David M. Polen
Polen Capital Management
Polen Capital Management Portfolio 13F
Polen Capital Management Holdings Activity
- Portfolio value:
- $4.45B≈ (-$130M≈)
- Previous value:
- $4.58B≈
- # of changes:
- 26
- New positions:
- 1
- Reported for:
- 30 Sep 2014 (Q3)
- Latest filing date:
- 14 Nov 2014
Polen Capital Management has disclosed a total of 26 changes to the portfolio in the (2014 Q3) SEC report(s): increased the number of shares of 4, bought 1 totally new, decreased the number of shares of 17 and completely sold out 4 position(s).
What stocks did Polen Capital Management buy in 2014 Q3?
During 2014 Q3 Polen Capital Management has purchased 5 securities: (TJX) The TJX Companies Inc (added shares +30.32%), (REGN) Regeneron Pharmaceuticals Inc (added shares +164.59%), (BKNG) Booking Holdings Inc (added shares +91.98%), (ORLY) OReilly Automotive Inc (new buy) and (IWF) iShares Russell 1000 Growth ETF (added shares +16.12%).
In the 2014 Q3 report(s) the following changes have been made to the top investments: (AGN-OLD) ALLERGAN INC/UNITED STATES (reduced shares -2.93%), (V) Visa Inc, CL-A (reduced shares -3.14%), (NKE) Nike Inc (reduced shares -3.02%), (ABT) Abbott Laboratories (reduced shares -2.88%) and (ORCL) Oracle Corp (reduced shares -3.21%).
26 results
| History | Ticker | Name |
% or activity |
Shares change |
Shares held after* |
% change to portfolio |
Reported price* |
% difference current price* |
% of portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
OReilly Automotive Inc
|
new
|
$10.02
|
+832.96%($93.52)
|
3.00%
|
2014 Q3
|
≈ 0.25 years
|
||||
|
|
Regeneron Pharmaceuticals Inc
|
+164.59%
|
$360.52
|
+113.86%($771.00)
|
4.47%
|
2013 Q2 or earlier
|
≈ 1.50+ years
|
||||
|
|
Booking Holdings Inc
|
+91.98%
|
$46.34
|
+348.51%($207.86)
|
3.97%
|
2014 Q2
|
≈ 0.50 years
|
||||
|
|
The TJX Companies Inc
|
+30.32%
|
$29.58
|
+438.62%($159.35)
|
5.17%
|
2013 Q4
|
≈ 1.00 year
|
||||
|
|
iShares Russell 1000 Growth ETF
|
+16.12%
|
$22.90
|
+443.52%($124.47)
|
0.03%
|
2013 Q4
|
≈ 1.00 year
|
||||
|
|
Abbott Laboratories
|
-2.88%
|
$41.59
|
+151.62%($104.65)
|
6.54%
|
2013 Q2 or earlier
|
≈ 1.50+ years
|
||||
|
|
ALLERGAN INC/UNITED STATES
|
-2.93%
|
$178.19
|
|
9.80%
|
2013 Q2 or earlier
|
≈ 1.50+ years
|
||||
|
|
Gartner Inc
|
-2.94%
|
$73.47
|
+153.74%($186.42)
|
3.61%
|
2013 Q2 or earlier
|
≈ 1.50+ years
|
||||
|
|
Automatic Data Processing Inc
|
-3.01%
|
$83.08
|
+224.74%($269.79)
|
4.25%
|
2013 Q3
|
≈ 1.25 years
|
||||
|
|
Nike Inc
|
-3.02%
|
$44.60
|
-6.28%($41.80)
|
6.79%
|
2013 Q2 or earlier
|
≈ 1.50+ years
|
||||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.